{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T22:02:06Z","timestamp":1757628126183,"version":"3.44.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF21OC0072020"],"award-info":[{"award-number":["NNF21OC0072020"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-08989-2","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T09:24:05Z","timestamp":1756113845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The DEXA-PSYCH Study\u2014dexamethasone for moderate-to-severe depression: study protocol for a double-blind, randomized, parallel-group, placebo-controlled trial"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0832-2667","authenticated-orcid":false,"given":"Troels Boldt","family":"R\u00f8mer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla G\u00f8tzsche","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pernille B\u00f8lling","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rune Haubo Bojesen","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Eriksen","family":"Benros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"8989_CR1","doi-asserted-by":"crossref","unstructured":"Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011 Jul 26 [cited 2021 Apr 8];9(1):90. Available from: http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/1741-7015-9-90.","DOI":"10.1186\/1741-7015-9-90"},{"key":"8989_CR2","unstructured":"Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: A systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2015 Aug 22 [cited 2021 Apr 8];386(9995):743\u2013800. Available from: http:\/\/www.thelancet.com\/article\/S0140673615606924\/fulltext."},{"key":"8989_CR3","doi-asserted-by":"crossref","unstructured":"Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 2007 [cited 2022 Apr 14];68(6):899\u2013907. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17592915\/.","DOI":"10.4088\/JCP.v68n0612"},{"key":"8989_CR4","doi-asserted-by":"crossref","unstructured":"Nordentoft M, Mortensen PB, Pedersen CB. Absolute risk of suicide after first hospital contact in mental disorder. Arch Gen Psychiatry. 2011 Oct [cited 2022 Apr 14];68(10):1058\u201364. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21969462\/.","DOI":"10.1001\/archgenpsychiatry.2011.113"},{"key":"8989_CR5","doi-asserted-by":"crossref","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. 2018 Apr 7 [cited 2021 Apr 8];391(10128):1357\u201366. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29477251\/.","DOI":"10.1016\/S0140-6736(17)32802-7"},{"key":"8989_CR6","unstructured":"National Institute for Health and Care Excellence (NICE). Depression in adults: Treatment and management (NG222). 2022. Available at: https:\/\/www.nice.org.uk\/guidance\/ng222 . Accessed 23 Mar 2023."},{"issue":"11","key":"8989_CR7","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905\u201317.","journal-title":"Am J Psychiatry"},{"key":"8989_CR8","doi-asserted-by":"crossref","unstructured":"Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. Major depressive disorder. Vol. 2, Nature Reviews Disease Primers. Nature Publishing Group; 2016. p. 1\u201320.","DOI":"10.1038\/nrdp.2016.65"},{"key":"8989_CR9","doi-asserted-by":"crossref","unstructured":"Cassano P, Fava M. Tolerability issues during long-term treatment with antidepressants. Vol. 16, Annals of Clinical Psychiatry. Ann Clin Psychiatry; 2004. p. 15\u201325.","DOI":"10.1080\/10401230490281618"},{"issue":"1","key":"8989_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/acps.12301","volume":"131","author":"WW IsHak","year":"2015","unstructured":"IsHak WW, Mirocha J, James D, Tobia G, Vilhauer J, Fakhry H, et al. Quality of Life in Major Depressive Disorder Before\/After Multiple Steps of Treatment and One-year Follow-up. Acta Psychiatr Scand. 2015Jan 1;131(1):51.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"8989_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/acps.13335","volume":"144","author":"P Cuijpers","year":"2021","unstructured":"Cuijpers P, Karyotaki E, Ciharova M, Miguel C, Noma H, Furukawa TA. The effects of psychotherapies for depression on response, remission, reliable change, and deterioration: A meta-analysis. Acta Psychiatr Scand. 2021Sep 1;144(3):288\u201399.","journal-title":"Acta Psychiatr Scand"},{"key":"8989_CR12","doi-asserted-by":"crossref","unstructured":"Ropper AH, Espinoza RT, Kellner CH. Electroconvulsive Therapy. Ropper AH, editor. 101056\/NEJMra2034954. 2022 Feb 16 [cited 2022 Apr 14];386(7):667\u201372. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMra2034954","DOI":"10.1056\/NEJMra2034954"},{"key":"8989_CR13","doi-asserted-by":"crossref","unstructured":"Kim J, Farchione T, Potter A, Chen Q, Temple R. Esketamine for Treatment-Resistant Depression \u2014 First FDA-Approved Antidepressant in a New Class. New England Journal of Medicine . 2019 Jul 4 [cited 2021 Jul 1];381(1):1\u20134. Available from: https:\/\/www-nejm-org.ep.fjernadgang.kb.dk\/doi\/10.1056\/NEJMp1903305","DOI":"10.1056\/NEJMp1903305"},{"key":"8989_CR14","doi-asserted-by":"crossref","unstructured":"Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM. Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29 [cited 2022 Mar 8];35(3):722\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20406665\/.","DOI":"10.1016\/j.pnpbp.2010.04.011"},{"key":"8989_CR15","doi-asserted-by":"crossref","unstructured":"Kadmiel M, Cidlowski JA. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci. 2013 Sep [cited 2022 Jan 17];34(9):518. Available from: https:\/\/www.pmc\/articles\/PMC3951203\/.","DOI":"10.1016\/j.tips.2013.07.003"},{"issue":"6","key":"8989_CR16","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1136\/ard.2009.127332","volume":"69","author":"SL Gorter","year":"2010","unstructured":"Gorter SL, Bijlsma JW, Cutolo M, Gomez-Reino J, Kouloumas M, Smolen JS, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010Jun 1;69(6):1010\u20134.","journal-title":"Ann Rheum Dis"},{"key":"8989_CR17","doi-asserted-by":"crossref","unstructured":"Hardy JR, Rees E, Ling J, Burman R, Feuer D, Broadley K, et al. A prospective survey of the use of dexamethasone on a palliative care unit. Palliat Med. 2001 [cited 2022 Jan 28];15(1):3\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11212465\/.","DOI":"10.1191\/026921601673324846"},{"key":"8989_CR18","doi-asserted-by":"crossref","unstructured":"Paulsen \u00d8, Klepstad P, Rosland JH, Aass N, Albert E, Fayers P, et al. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J Clin Oncol. 2014 Oct 10 [cited 2022 Jan 28];32(29):3221\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25002731\/.","DOI":"10.1200\/JCO.2013.54.3926"},{"key":"8989_CR19","doi-asserted-by":"crossref","unstructured":"Group TRC. Dexamethasone in Hospitalized Patients with Covid-19. 101056\/NEJMoa2021436\n. 2020 Jul 17;384(8):693\u2013704.","DOI":"10.1056\/NEJMoa2021436"},{"key":"8989_CR20","doi-asserted-by":"crossref","unstructured":"Orlovska-Waast S, Benros ME, Orlovska-Waast S, Benros ME. Autoimmune Diseases and Infections as Risk Factors for Mental Disorders. Immuno-Psychiatry. 2021 [cited 2022 Apr 14];3\u201316. Available from: https:\/\/link.springer.com\/chapter\/10.1007\/978-3-030-71229-7_1","DOI":"10.1007\/978-3-030-71229-7_1"},{"issue":"2","key":"8989_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/acps.12671","volume":"135","author":"O K\u00f6hler","year":"2017","unstructured":"K\u00f6hler O, Petersen L, Mors O, Mortensen PB, Yolken RH, Gasse C, et al. Infections and exposure to anti-infective agents and the risk of severe mental disorders: a nationwide study. Acta Psychiatr Scand. 2017;135(2):97\u2013105.","journal-title":"Acta Psychiatr Scand"},{"key":"8989_CR22","doi-asserted-by":"crossref","unstructured":"Benros ME, Waltoft BL, Nordentoft M, Ostergaard SD, Eaton WW, Krogh J, et al. Autoimmune diseases and severe infections as risk factors for mood disorders a nationwide study. JAMA Psychiatry. 2013 [cited 2021 Apr 8];70(8):812\u201320. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23760347\/.","DOI":"10.1001\/jamapsychiatry.2013.1111"},{"key":"8989_CR23","doi-asserted-by":"crossref","unstructured":"Orlovska-Waast S, K\u00f6hler-Forsberg O, Brix SW, Nordentoft M, Kondziella D, Krogh J, et al. Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. Vol. 24, Molecular Psychiatry. Nature Publishing Group; 2019. p. 869\u201387.","DOI":"10.1038\/s41380-018-0220-4"},{"key":"8989_CR24","doi-asserted-by":"crossref","unstructured":"K\u00f6hler\u2010Forsberg O, N. Lydholm C, Hjorth\u00f8j C, Nordentoft M, Mors O, Benros ME. Efficacy of anti\u2010inflammatory treatment on major depressive disorder or depressive symptoms: meta\u2010analysis of clinical trials. Acta Psychiatr Scand. 2019 May 28 [cited 2021 Apr 8];139(5):404\u201319. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/acps.13016","DOI":"10.1111\/acps.13016"},{"key":"8989_CR25","doi-asserted-by":"crossref","unstructured":"Arana GW, Santos AB, Laraia MT, McLeod-Bryant S, Beale MD, Rames LJ, et al. Dexamethasone for the Treatment of Depression: A Randomized, Placebo-Controlled, Double-Blind Trial. American Journal of Psychiatry. 1995 [cited 2021 Apr 8];152(2):265\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/7840362\/.","DOI":"10.1176\/ajp.152.2.265"},{"key":"8989_CR26","doi-asserted-by":"crossref","unstructured":"DeBattista C, Posener JA, Kalehzan BM, Schatzberg AF. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: A double-blind, placebo-controlled study. American Journal of Psychiatry. 2000 Aug 1 [cited 2021 Apr 8];157(8):1334\u20137. Available from: http:\/\/psychiatryonline.org\/doi\/abs\/10.1176\/appi.ajp.157.8.1334","DOI":"10.1176\/appi.ajp.157.8.1334"},{"issue":"9","key":"8989_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257946","volume":"16","author":"R Jeppesen","year":"2021","unstructured":"Jeppesen R, Orlovska-Waast S, S\u00f8rensen NV, Christensen RHB, Benros ME. Immunological investigations of the cerebrospinal fluid in patients with recent onset psychotic disorders: a study protocol. PLoS One. 2021;16(9): e0257946. https:\/\/doi.org\/10.1371\/journal.pone.0257946.","journal-title":"PLoS One"},{"key":"8989_CR28","doi-asserted-by":"crossref","unstructured":"Miloslavsky EM, Naden RP, Bijlsma JWJ, Brogan PA, Brown ES, Brunetta P, et al. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017 Mar 1 [cited 2022 Jan 18];76(3):543\u20136. Available from: https:\/\/ard.bmj.com\/content\/76\/3\/543.","DOI":"10.1136\/annrheumdis-2016-210002"},{"key":"8989_CR29","doi-asserted-by":"crossref","unstructured":"Lingj\u00e6rde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987 [cited 2022 Jan 19];76:1\u2013100. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/j.1600-0447.1987.tb10566.x","DOI":"10.1111\/j.1600-0447.1987.tb10566.x"},{"key":"8989_CR30","doi-asserted-by":"crossref","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nature Reviews Drug Discovery 2018 18:1. 2018 Oct 12 [cited 2022 Mar 8];18(1):41\u201358. Available from: https:\/\/www.nature.com\/articles\/nrd.2018.168.","DOI":"10.1038\/nrd.2018.168"},{"key":"8989_CR31","doi-asserted-by":"crossref","unstructured":"Bagby RM, Ryder AG, Schuller DR, Marshall MB. The Hamilton Depression Rating Scale: has the gold standard become a lead weight? Am J Psychiatry. 2004 Dec [cited 2022 Apr 14];161(12):2163\u201377. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15569884\/.","DOI":"10.1176\/appi.ajp.161.12.2163"},{"key":"8989_CR32","doi-asserted-by":"crossref","unstructured":"Svanborg P, \u00c5sberg M. A comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery Asberg Depression Rating Scale (MADRS). J Affect Disord . 2001 [cited 2022 Apr 14];64(2\u20133):203\u201316. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11313087\/.","DOI":"10.1016\/S0165-0327(00)00242-1"},{"key":"8989_CR33","doi-asserted-by":"crossref","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 [cited 2022 Apr 14];134(4):382\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/444788\/.","DOI":"10.1192\/bjp.134.4.382"},{"key":"8989_CR34","doi-asserted-by":"crossref","unstructured":"Mittmann N, Mitter S, Borden EK, Herrmann N, Naranjo CA, Shear NH. Montgomery-Asberg severity gradations. Am J Psychiatry. 1997 [cited 2022 Apr 14];154(9):1320\u20131. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9286204\/.","DOI":"10.1176\/ajp.154.9.1320b"},{"key":"8989_CR35","doi-asserted-by":"crossref","unstructured":"Galinowski A, Lehert P. Structural validity of MADRS during antidepressant treatment. Int Clin Psychopharmacol. 1995 [cited 2022 Apr 14];10(3):157\u201361. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/8675968\/.","DOI":"10.1097\/00004850-199510030-00004"},{"key":"8989_CR36","doi-asserted-by":"crossref","unstructured":"Bech P, Tangh\u00f8j P, Andersen H, Over\u00f8 K. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berl) . 2002 [cited 2022 Apr 14];163(1):20\u20135. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12185396\/.","DOI":"10.1007\/s00213-002-1147-6"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08989-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08989-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08989-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:50:47Z","timestamp":1757483447000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08989-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8989"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08989-2","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Recruitment, screening, and enrollment commenced after approval from the Danish Medicines Agency, Ethics Committee, and the Capital Region Knowledge Center for Data Compliance. All documents and correspondences pertaining to the approval are publicly available through CTIS. Written, informed consent to participate will be obtained from all participants as described above.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Model consent forms and written patient information details the consent for publication of overall trial data. Both documents were approved by the Danish authorities in accordance with Danish law.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"303"}}